EXTON, Pa.—September 5, 2013—ThingWorx™ today announced that Biocartis, an innovative molecular diagnostics company, has selected ThingWorx as the Machine-to-Machine (M2M) application platform to power its next-generation remote service offering. Biocartis intends to use the ThingWorx application platform to provide remote instrument connectivity and innovative M2M applications, extending its molecular diagnostics solution with high-value remote service and value-added offerings for its customers and partners.
ThingWorx enables Biocartis to bring to market a next-generation remote service solution for its Molecular Diagnostics Platform, a unique DNA-based in vitro diagnostics system that it is currently developing for the emerging needs of personalized medicine. Biocartis is utilizing the rapid application development tools and M2M communications technology provided by the ThingWorx platform to develop the remote service solution. Using the extensibility and enterprise integration features that are core to the ThingWorx platform, Biocartis aims to deliver innovative, value-added services in addition to remote instrument monitoring.
“We are entering the ‘connected age’, an age that brings people, systems, and the ‘50 billion things’—sensors, devices, machines—together to provide the opportunity for a step change in operational innovation and resource efficiency,” said Rudi Pauwels, CEO of Biocartis. “ThingWorx uniquely enables organizations to rapidly build and run connected applications to capture the business opportunities offered by the emerging pervasiveness of smart things.”
“We are pleased to be selected by Biocartis, an innovator in the molecular diagnostics industry,” said Russ Fadel, CEO of ThingWorx. “The rapid time to market provided by ThingWorx, combined with the platform’s unique connectivity and business integration capabilities, enables our customers to create a competitive advantage in their markets. Biocartis’ selection of ThingWorx further validates our position as the leader in next-generation connected application development.”
Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis’ ambition is to establish a new gold standard in diagnostic testing.
Biocartis’ innovative research and diagnostic systems are characterized by multiplex detection and simplified workflows, which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays that have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients.
Biocartis is a rapidly growing company; to date Biocartis staff includes over 150 people. In December 2012, Biocartis launched its High Multiplex Detection Platform, and has thus evolved from a late-stage development company into a commercial business. For more information, visit www.biocartis.com.
ThingWorx™ provides the first platform designed to efficiently build and run the applications of today’s connected world. ThingWorx’s model-based design and search-based intelligence reduces application development efforts by 10X, minimizing cost, risk and time to market. The ThingWorx platform combines the key functionality of Web 2.0, search, and social collaboration, and applies it to the world of “things”, including connected products, machines, sensors, and industrial equipment. Businesses use the ThingWorx platform to rapidly deliver innovative applications and connected solutions across markets ranging from manufacturing, energy, and food, to Machine-to-Machine (M2M) remote monitoring and service, as well as in emerging Internet of Things applications, including smart cities, smart grid, agriculture, and transportation. For more information, please visit our website at www.thingworx.com and our blog at www.thingworx.com/blog or follow us on Twitter at @ThingWorx.
# # #